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Abstract
Background: The host, microbial, and environmental factors that contribute to variation in tuberculosis (TB) disease
are incompletely understood. Accumulating evidence suggests that one driver of geographic variation in TB disease
is the local ecology of mycobacterial genotypes or strains, and there is a need for a comprehensive and systematic
synthesis of these data. The objectives of this study were to (1) map the global distribution of genotypes that cause
TB disease and (2) examine whether any epidemiologically relevant clinical characteristics were associated with those
genotypes.
Methods: We performed a systematic review of PubMed and Scopus to create a comprehensive dataset of human TB
molecular epidemiology studies that used representative sampling techniques. The methods were developed
according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We extracted
and synthesized data from studies that reported prevalence of bacterial genotypes and from studies that
reported clinical characteristics associated with those genotypes.
Results: The results of this study are twofold. First, we identified 206 studies for inclusion in the study, representing
over 200,000 bacterial isolates collected over 27 years in 85 countries. We mapped the genotypes and found that,
consistent with previously published maps, Euro-American lineage 4 and East Asian lineage 2 strains are widespread,
and West African lineages 5 and 6 strains are geographically restricted. Second, 30 studies also reported transmission
chains and 4 reported treatment failure associated with genotypes. We performed a meta-analysis and found substantial
heterogeneity across studies. However, based on the data available, we found that lineage 2 strains may be associated
with increased risk of transmission chains, while lineages 5 and 6 strains may be associated with reduced risk, compared
with lineage 4 strains.
Conclusions: This study provides the most comprehensive systematic analysis of the evidence for diversity in bacterial
strains that cause TB disease. The results show both geographic and epidemiological differences between strains, which
could inform our understanding of the global burden of TB. Our findings also highlight the challenges of collecting the
clinical data required to inform TB diagnosis and treatment. We urge future national TB programs and research efforts to
prioritize and reinforce clinical data collection in study designs and results dissemination.
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Background
Tuberculosis (TB) is found in every population of the
world today and kills 1.1–1.6 million people globally each
year [1]. There is also significant geographic variation in
the prevalence, incidence, and mortality of TB [1]. The
factors that contribute to individual and geographic vari-
ation in TB infection and disease are incompletely under-
stood. An intact immune response is required to prevent
infection and progression to active disease as conditions
that weaken the immune system are strongly associated
with TB, including HIV co-infection, type II diabetes mel-
litus, undernutrition, and immunosuppressive medications
such as anti-tumor necrosis factor (TNF) therapy [2]. En-
vironmental factors likely also play a role in infection and
disease progression, including population density, indoor
and outdoor air pollution, and health care quality and ac-
cess [2]. However, these risk factors are insufficient to ex-
plain the current burden of TB [3].
An additional driver of variation may be human and
bacterial genetic variation [4]. There are human genetic
polymorphisms associated with susceptibility to latent
TB infection and progression to active disease [5], as
well as polymorphisms in the Mycobacterium tubercu-
losis complex (MTBC) associated with the ability to
cause disease [6] and with transmissibility [7]. The
host-pathogen relationship in TB is sympatric [8], i.e.,
the host and pathogen tend to share a common ancestral
geographic origin [8]. When patients are infected with
an allopatric strain or a strain that originates from a dif-
ferent geographic origin than the patient, they may be at
risk for greater pulmonary impairment [9]. Similarly,
there is evidence for associations between human
leukocyte antigen (HLA) type and susceptibility to TB
disease caused by particular MTBC strains [10, 11].
However, there is considerable variation in studies that
test for associations between MTBC genotypes and clin-
ical characteristics [12, 13].
A better understanding of MTBC molecular epidemi-
ology could improve our ability to treat and control TB.
Genetic data are already being used by epidemiologists as
tools for outbreak investigations to identify sources of
mycobacterial infection [14] and as tools in surveillance to
identify the strains most likely to spread rapidly through
new human populations [3]. Additionally, understanding
the risk factors associated with MTBC genetic data could
help direct the development of biomarker-based diagnos-
tic tests to identify patients early that are infected with
strains associated with higher risk of treatment failure, re-
lapse, drug resistance, or death [15]. Finally, there is accu-
mulating evidence for variation in the immune response
to distinct MTBC strains [16–21]. Therefore, understand-
ing the global variation in MTBC strains will be important
as new vaccines, biomarkers, and host-directed therapies
are developed [13].
The objective of this study was to systematically
synthesize all available information on MTBC genotypes
in order to (1) map the global distribution of genotypes
that cause TB disease and (2) determine whether any ep-
idemiologically relevant clinical characteristics were
associated with those genotypes. Previous systematic re-
views that mapped MTBC genotype distribution focused
on MTBC Beijing family strains and their association
with drug resistance [22, 23]. We expanded on this pre-
vious work by considering data for all MTBC lineages,
making this the most comprehensive synthesis of MTBC
genotypes that has been conducted to date.
Methods
The methods for this systematic review, including litera-
ture search, inclusion criteria, and analysis, were developed
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) [24, 25].
Information sources and search strategy
We identified studies by systematically searching PubMed
and Scopus. The first search was run on June 8, 2017, and
the final search was run on November 13, 2017. Articles
identified in these searches were supplemented by six pub-
lished studies in Papua New Guinea, India, Botswana,
Nepal, Ethiopia, and Kenya, and two unpublished studies in
Mexico and Panama, which we were directed to by manu-
ally checking the reference lists of studies and by reviewing
the conference abstracts for the 48th Union World Confer-
ence on Lung Health. Complete details of search strings
and dates searched are found in Additional file 1.
Eligibility criteria
Types of studies
In order to minimize sampling bias in the analysis, we re-
stricted our analysis to human TB molecular epidemiology
studies that used either probability sampling methods,
such as random or cluster-based sampling, or that col-
lected samples from all reported or all new TB cases in
the study location and time period. For the majority of
studies “all TB cases” included culture-positive TB cases
only. For studies that used GeneXpert remnants for DNA
collection, this included microscopy-positive TB cases.
We excluded studies of sub-populations that may over- or
underrepresent particular genotypes, such as studies re-
stricted to hospital workers, prisoners, HIV-infected indi-
viduals, children, homeless individuals, immigrants,
individuals living in slums, military personnel, individuals
with drug-resistant strains, relapse or re-infection cases,
or extrapulmonary TB cases. In addition, we excluded
outbreak investigations, case studies, review articles, and
studies not available in English or Spanish. When multiple
studies used the same data, we included the study that
provided the most detailed genotyping data and/or the
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most detailed corresponding clinical data. For the global
mapping analysis, we excluded studies that only tested or
reported data for one lineage. These latter studies were
considered for the clinical characteristics analysis. We did
not apply publication date restrictions.
Types of genotyping methods
We included studies that reported genotyping results by
geographic location, year, and sampling method and that
met the eligibility criteria described above. We consid-
ered genotypes determined by whole-genome sequen-
cing (WGS), large sequence polymorphism (LSP) as
determined by polymerase chain reaction (PCR), spacer
oligonucleotide typing (spoligotyping), and multi-locus
variable number of tandem repeats (VNTR) analysis
(MLVA).
Types of clinical characteristics
In a secondary step, we screened all studies that met
our initial inclusion criteria for studies that also re-
ported clinical characteristics associated with geno-
types, including transmission chains, progression to
active TB, treatment failure, duration of symptoms,
relapse or retreatment, severity of pulmonary lesions,
and extrapulmonary TB. For further analysis, we fo-
cused on the characteristics with clear case definitions
and sufficient data available for meta-analysis, which
included treatment failure and transmission chains.
Treatment failure was defined as a TB case that had
a positive sputum culture and/or smear at 5–8 months
following the start of TB treatment. Transmission
chains were inferred by genetic clusters, which were
defined as two or more identical genotype patterns
identified in the same study location and time period
[26]. Genetic clustering appears not to be a perfect
measure of transmission chains since it can be im-
pacted by various factors including social mixing, im-
migration, age structure, and underlying TB incidence
[27, 28]. However, we decided that it was an import-
ant measure to include because (1) it has been an im-
portant tool for TB surveillance [29–31] and (2) it
currently has sufficient published data available for
global analysis.
Data collection process and data items
Study screening and selection
Articles were reviewed for eligibility first by screening
the titles and abstracts and then by reviewing the full
texts in an unblinded standardized manner. One re-
viewer screened the titles and abstracts, and the selected
articles were divided between three reviewers to screen
and extract using a standardized data extraction form.
When there was uncertainty about the eligibility, re-
viewers arrived at a decision by consensus.
Genotype data extraction
Information that was extracted from each study included
(1) page number and table or figure the data was ex-
tracted from, (2) underlying study design [cohort or
cross-sectional], (3) sampling approach [all cases, all
new cases, cluster-based sample, or random sample], (4)
geographic region and year(s) the sample represented,
(5) genotyping method [spoligotyping, MLVA typing,
PCR, or WGS], and (6) total count of each genotype
identified in the sample. Additional file 2 contains the
screening sheet detailing all studies reviewed, reason(s)
for exclusion, and a log of any follow-up. Additional file 3
contains all raw genotyping data extracted and corre-
sponding study meta-data. The original extraction sheet
is available upon request.
Clinical characteristic data extraction
All studies that reported transmission chains or genetic
clustering as defined above were included in a second ex-
traction sheet. The following additional data were ex-
tracted in this sheet: (1) the total count of each genotype,
(2) total count of each genotype that was part of a genetic
cluster, and (3) potential confounders, when available (in-
cluding the proportion of HIV co-infection and drug re-
sistance in the sample, the mean age of the participants,
and the proportion of participants that were male, had
previously been diagnosed with TB, had extrapulmonary
TB, or were immigrants). Additional file 4 contains raw
genetic clustering data extracted and corresponding study
meta-data.
Synthesis and analysis
Classification system for genotypes
In this study, we defined “strains” based on the seven
phylogenetic lineages identified by S. Gagneaux and col-
leagues [32]. We included data on animal lineage strains
isolated from human TB cases, which included Mycobac-
terium bovis, Mycobacterium pinnipedii, Mycobacterium
caprae, Mycobacterium origys, and Mycobacterium microti
strains. Some studies reported “other,” “unknown,” “un-
defined,” “unclear,” or “uncommon” genotypes, which we
labeled as “unknown lineages.” For each study, we ex-
tracted data at the most detailed genotype level available.
When spoligotype octal codes were provided, we deter-
mined phylogenetic lineage using the central Bayesian net-
work (CBN) method implemented in Run TB-Lineage
[33, 34]. When spoligotype clade or family was provided,
we used SITVIT Web and Run TB-Lineage to determine
phylogenetic lineage [35]. When MLVA family was pro-
vided, we determined phylogenetic lineage using MIRU-
VNTRplus [36, 37]. For Ethiopian MLVA families, we
assigned strains to lineage 4 or lineage 7 using genetic re-
latedness based on published phylogenies [38, 39]. We im-
plemented this method directly in the extraction sheet
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using Excel formulas. Additional file 1: Table S1 illustrates
the online tools used in this method and Additional file 1:
Table S2 and Additional file 5 detail how individual geno-
types were related based on this method.
Data quality checks
We performed several data quality checks using code writ-
ten in R software (version 3.3.3) to check for duplicate ex-
tractions and for discrepancies between the screening and
extraction sheets. We checked that all extracted studies
were included in the screening sheet, and vice versa, using
PubMed ID or a unique study identifier. We checked for
duplicate extractions by looking for any studies that (1)
had duplicate PubMed ID or unique study identifiers, (2)
had the same country and start year, or (3) had the same
country and sample size. Each potentially duplicated or
missed study was checked manually, and the decision to
include or exclude was recorded.
Proportion of estimated TB cases represented in each
country
We determined the proportion of estimated TB cases that
were represented in each country for which we had data
using estimates from the Global Burden of Disease Study
2016 [40]. We downloaded estimates of the total number
of TB cases prevalent in each country and year across all
ages and sexes from https://vizhub.healthdata.org/gbd-
compare/ (accessed on July 29, 2018). We matched these
country-year estimates to each study based on the country
the study was conducted in and the year that corre-
sponded to the mid-point of its sampling period. We di-
vided the sample size of each study by the estimated
prevalent TB cases in the corresponding country and year
to get the proportion represented in each study. We then
summed the proportions represented in all studies within
each country to get final estimates of the proportion of TB
cases represented per country.
Map of the global distribution of genotypes
We determined the proportion of each phylogenetic
lineage present in each country for which we had data. If
multiple studies were available in a country, we summed
the strain counts across all studies and years to get the
final proportions and sample sizes.
Meta-analysis of genetic clustering association with
genotypes
We performed a random effects (RE) meta-analysis of
the relative risk (RR) of genetic clustering associated
with genotypes using the Reliability Method (RELM)
method in the R software package “metafor” (version
3.3.3) [41]. We excluded studies that identified fewer
than two isolates of the lineages under analysis. We ex-
amined inconsistency across studies using the I2 test that
measures the percentage of total variation across studies
due to heterogeneity [42]. We performed a subgroup
analysis of genetic clustering within the regions West
Asia, East Asia, Europe and the Americas, and Africa.
Results
Study selection
We identified 206 studies for inclusion in the study, repre-
senting over 200,000 bacterial isolates collected over
27 years in 85 countries. Of these studies, 30 also reported
transmission chains and 4 reported treatment failure associ-
ated with genotypes. Figure 1 shows the PRISMA flow dia-
gram detailing the study selection process. Additional file 1:
Figure S1 shows a map of the numbers of studies per year
that were included from each country.
Study variation
The 206 studies included 42 nationally representative
samples and 164 samples representative of smaller geo-
graphic units. These included 34 studies that used a
cluster or random sampling, 170 that collected samples
from all reported or new TB cases in a given geographic
location and time period, and 2 studies that used differ-
ent sampling methods for different time periods. We il-
lustrated how these study designs varied globally in
Fig. 2. Sub-Saharan Africa was dominated by subnation-
ally representative studies, while Caribbean Latin Amer-
ica was dominated by nationally representative studies
(Fig. 2). In addition, we calculated the proportion of esti-
mated prevalent TB cases that were represented in each
country. Proportions ranged from 0.0012% in Nigeria to
5.4% in Greenland (Fig. 2). In general, the proportions
were lower in countries where TB burden was highest
(Fig. 2). The meta-data linked with each individual study
is available in its raw format in Additional file 3.
Geographic variation in MTBC genotypes
We mapped the distribution of MTBC genotypes identi-
fied in our systematic review across all years and for all lo-
cations in each country for which we had data. A striking
feature of the map was the widespread global distribution
of Euro-American lineage 4 (Figs. 3 and 4). Lineage 4 was
identified in every country where genotyping data was
available for inclusion, and it was the majority lineage in
52 of the 85 countries (Additional file 1: Table S3). Our
map also showed the fairly widespread distribution of East
Asian lineage 2 (Figs. 3 and 4), which was identified in 67
of the 85 countries and was the majority lineage in 6
countries (Additional file 1: Table S3). In contrast, West
African lineages 5 and 6 were identified in only 30 coun-
tries and were the majority lineages in zero countries
(Additional file 1: Table S2). In addition, Indo-Oceanic
lineage 1 and East African-Indian lineage 3 were identified
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in 64 and 59 countries, respectively, and each was the ma-
jority lineage in 2 countries (Additional file 1: Table S3).
The map also illustrated various regions of distinct myco-
bacterial distribution that may be independent of geopolitical
country boundaries (Fig. 3 and Additional file 1: Figure S2).
For example, Eastern Africa from Sudan to Mozambique
was distinct from the rest of Africa in that it had a higher
prevalence of lineages 1 and 3. Western Africa was distinct
in that it had the highest prevalence of lineages 5 and 6,
while Southern Africa had the highest prevalence of lineage
2 strains and Central Africa had the highest prevalence of
lineage 4 strains. In addition, the Indian subcontinent and
Australia had a similar genotype distribution, which was dis-
tinct from Russia and Eastern Asia. The UK was distinct
from the rest of Europe in that it had a greater prevalence of
lineages 1 and 3. Finally, Central America and northern
South America had distinct genotype distributions from cen-
tral and southern South America.
Temporal variation in MTBC genotypes
The results described above represent MTBC genotype
distributions aggregated across all years from 1990 to
2017. In order to investigate the changes over time in
genotype distribution, and to illustrate the time periods
that more accurately represented the data in each coun-
try, we created maps of genotype distribution for three
distinct time periods (Additional file 1: Figure S3). To
synthesize these data, we plotted the total prevalence of
each lineage in each time period by region (Fig. 5). Fig-
ure 5 should be used as a guide and interpreted with
some caution as it represents data aggregated across di-
verse geographic locations. The plots showed that
lineage 3 strains have increased in prevalence over time
in the UK (Additional file 1: Figure S3A-C) and Europe
(Fig. 5). In addition, the plots showed a decline in the
prevalence of lineage 1 in West and Central Asia (Fig. 5
and Additional file 1: Figure S3B-C).
Clinical variation in MTBC genotypes
Transmission chains as measured by genetic clustering
We performed a random-effects meta-analysis [41] of the
30 studies that reported transmission chains or genetic
clusters associated with MTBC genotypes. We defined
genetic clusters as two or more identical genotype patterns
Fig. 1 PRISMA flow diagram. Diagram illustrating the literature selection process, including identification, screening, eligibility, and total studies
included in the global analysis and clinical characteristic analysis. Reasons for exclusion of full texts are detailed. Individual-level details of each
study reviewed are found in Additional file 2
Wiens et al. BMC Medicine          (2018) 16:196 Page 5 of 13
identified in the same study location and time period. We
used lineage 4 as the reference group because lineage 4
strains were identified in each study included in the
meta-analysis. The characteristics of each study included
in the meta-analyses are shown in Additional file 1: Table
S4. We analyzed transmission chain relative risk (RR)
across all studies, as well as within subgroups of Africa,
East Asia, West Asia, and Europe and the Americas.
The results of the meta-analyses are summarized
in Table 1, and detailed forest plots are shown in
Additional file 1: Figure S4. Lineage 1 strains overall were
not associated with transmission chains (RR [95% CI] =
1.07 [0.83, 1.37]) (Table 1) but were associated with in-
creased risk within East Asia (RR [95% CI] = 2.54 [1.02,
6.28]) (Additional file 1: Figure S4A). Lineage 2 Beijing
strains were associated with increased risk of transmission
chains overall (RR [95% CI] = 1.24 [1.07, 1.45]) (Table 1),
and the risk was higher within East Asia (RR [95% CI] =
1.90 [1.14, 3.17]) (Additional file 1: Figure S4B). Lineage 3
strains were associated with reduced risk of transmission
chains in Europe and the Americas (RR [95% CI] = 0.67
[0.50, 0.91]) (Additional file 1: Figure S4C). Lineages 5 and
6 strains were associated with reduced risk of transmission
chains overall (RR [95% CI] = 0.61 [0.43, 0.86]) (Table 1,
Additional file 1: Figure S4D), as were animal lineage
strains (RR [95% CI] = 0.79 [0.64, 0.96]) (Table 1,
Additional file 1: Figure S4E). Unknown strains, which
comprise orphans, undefined, and uncommon geno-
types, were associated with reduced risk of transmis-
sion chains overall (RR [95% CI] = 0.56 [0.40, 0.79])
(Table 1, Additional file 1: Figure S4F).
RE meta-analysis of the RR of transmission chains asso-
ciated with each MTBC lineage compared with MTBC
lineage 4. Transmission chains in this analysis are defined
as identification of two or more MTBC isolates with iden-
tical genetic patterns in the same study location and time
period. “Cluster” indicates part of a transmission chain,
and “unique” indicates not part of a transmission chain.
Lineage 7 strains are grouped with “unknown” strains be-
cause there was insufficient data on these strains for
meta-analysis. We performed the analysis across all stud-
ies that we identified in the systematic review, as well as
within the regions West Asia, East Asia, Europe and the
Americas, and Africa. RE meta-analysis was performed
using the RELM method in R software package “metafor”
(version 3.3.3) [41]. Forest plots for each analysis are
shown in Additional file 1: Figure S4A-F.
These results should be interpreted with some caution
as I2 analysis showed significant heterogeneity across all
studies (Table 1), as well as within most subgroups
(Additional file 1: Figure S3), with a few exceptions.
There was low heterogeneity between studies in the
Fig. 2 Variation in sampling methods of studies included in the systematic review. Variation in study design for the 206 studies that met the
inclusion criteria for this systematic review. The proportion of studies in each country that collected a nationally representative sample versus a
sample representative of a smaller geographic location are shown in purple and green, respectively. Light purple and green indicate the proportion of
studies in each country that collected all reported or all new TB cases in a given location and time period. For the majority of studies, “all TB cases”
represents culture-positive cases only; for studies that use GeneXpert remnants for DNA collection, this represents microscopy-positive cases. Dark
purple and green indicate the proportion of studies in a given country that used a random or cluster-based survey sampling method to select a
subset of cases. TB cases in each country were estimated by the Global Burden of Disease Study 2016 [40]. We calculated percent of all TB cases in
each country using the total number of genotyped cases as the numerator and total estimated prevalent TB cases as the denominator. The radius of
each pie is proportional to percent of total estimated TB cases that are represented across all studies in each country. Examples of percent of total
estimated TB cases that correspond to pie sizes are shown in the legend in gray. The example pies show the minimum, mid-point, and maximum
percent of estimated TB cases represented in this review
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animal strains analysis (Table 1, I2 = 18%), as well as in the
analysis of lineages 5 and 6 strains within Europe and the
Americas (Additional file 1: Figure S3D, I2 = 0.0%).
Treatment failure
Several studies identified in the systematic review
showed that lineage 2 Beijing family strains were associ-
ated with treatment failure. Beijing strains were associ-
ated with treatment failure in Indonesia compared with
all other genotypes after adjusting for drug resistance,
non-adherence, age, diabetes mellitus, and severity of
radiological lesions (relative risk [95% CI] = 1.94 [1.26,
3.0]) (Table 2) [43]. Beijing strains were also associated
with treatment failure after adjusting for multi-drug re-
sistance in India (odds ratio [95% CI] = 3.29 [1.29, 8.14])
(Table 2) [44]. However, Beijing strains were not associ-
ated with treatment failure after adjusting for multi-drug
resistance in Vietnam (odds ratio [95% CI] = 0.7 [0.3,
2.0]) (Table 2) [45] and were not associated with treat-
ment failure of drug-susceptible TB in South Africa
(Table 2) [46]. Confounders that were not adjusted for
in all these studies, such as HIV co-infection, diabetes
mellitus, body mass index (BMI), cavitary TB, and qual-
ity of health care, may contribute to the variation in re-
sults (Table 2).
Summary of study design and findings for each study
reported genotype associations with treatment failure.
RR indicates relative risk, OR indicates odds ratio, and
95% CI indicates 95% confidence interval. The latter
measures were taken directly from the studies and were
not reanalyzed.
Discussion
To our knowledge, this study represents the most com-
prehensive dataset on MTBC lineages that has been cre-
ated by systematically assembled genotyping data from
studies that used representative sampling techniques.
The data show geographic variation in MTBC geno-
types, which is consistent with previously published
studies that used convenience samples and much smaller
datasets. We find some evidence for clinical variation
between genotypes, though, we also show significant
variation between studies, which highlights the need for
additional data.
Global variation in bacterial strains that cause TB disease
The results presented in this study are consistent with
previously published maps that showed that MTBC
strains that evolved more recently in human history—
lineage 2, lineage 3, and lineage 4 strains—tend to be
more widely distributed around the world [22, 35, 47,
Fig. 3 The global distribution and genetic diversity and of MTBC phylogenetic lineages. MTBC global genotype distribution by country across all
years based on a systematic review of TB molecular epidemiology studies employing one of four genotyping methods: (1) spoligotyping, (2)
MLVA typing, (3) PCR typing for large sequence polymorphisms, and (4) whole-genome sequencing. All genotyping methods are converted to a
common classification system based on phylogenetic lineages (Additional file 1: Tables S1 and S2), and pie charts show the proportion of lineages
present in each country where data was available and studies met our inclusion criteria. Indo-Oceanic lineage 1 is shown in pink, lineage 2 is shown in
blue, East African-Indian lineage 3 is shown in purple, Euro-American lineage 4 is shown in orange, West African lineages 5 and 6 are shown in green,
and Ethiopian lineage 7 is shown in yellow. “Unknown” represents strain types that were not identified by the authors either due to low frequency or
unknown genetic patterns. Studies that report prevalence of only one lineage and grouped all other genotypes as “other” are excluded from the map.
If multiple studies were available in a country, strain counts were summed across all studies to get final proportions and sample sizes. The radius of
each pie is proportional to the number of isolates collected in each country. Examples of sample sizes that correspond to pie sizes are shown in the
legend in gray. The example pies shown represent the minimum, mid-point, and maximum samples sizes
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48]. We also showed that lineage 1, lineage 2, and
lineage 3 are more prevalent in Europe and in North
and South America than shown in previously published
maps [35, 47, 48]. Moreover, we show that lineage 3
strains may be increasing in prevalence in Europe, while
lineage 1 strains may be decreasing in prevalence in
West Asia. These patterns in genotype distribution likely
reflect both historical and recent movement of strains
with people from East Asia and the Indian subcontinent
to Europe and the American continent. The dominance
of lineage 4 globally, and in particular in South Ameri-
can countries, also supports the hypothesis that Euro-
pean colonialists aided in the dispersion of this lineage
in the mid-sixteenth to nineteenth centuries [32, 48, 49].
If the first inhabitants of the American continent
brought early forms of lineage 2 strains with them when
they migrated from north-eastern Asia, these strains
may have been eliminated with the arrival of strains
from European colonialists.
Human migration is likely not the only determinant
of MTBC genotype distribution. Lineages 5 and 6 are
prevalent only in West Africa [35, 47, 48]. The reasons for
this geographic restriction are largely unknown but may
have to do with clinical characteristics of the patients in-
fected with these strains. Patients infected with lineage 6
are more likely than patients infected with other strains to
be older, HIV-infected, and severely malnourished [50]. In
addition, we showed that lineages 5 and 6 strains may be
less likely to cause transmission chains than lineage 4
strains and that these findings were more consistent in
Europe and the Americas than in Africa, which may re-
flect biological differences and/or social mixing which pre-
vents these strains from spreading through non-West
African populations. We also found that lineage 3 strains
were associated with reduced risk of transmission chains
in Europe and the Americas, which is consistent with the
findings from a household contact study in Montreal [51].
In contrast, we found that Beijing family strains may be
more likely to cause transmission chains, which could re-
flect the ability of Beijing strains to spread quickly through
human populations [46, 52, 53]. These findings are not
consistent with previous work that showed no differences
Fig. 4 Distribution of MTBC phylogenetic lineages by region. MTBC global genotype distribution by region corresponding to the data presented
in Fig. 3. Lineage proportions broken down by countries within each region are shown in Additional file 1: Table S3 and Figure S2
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between lineages in transmission from household contacts
[46, 54, 55]. Thus, further studies would be required to
confirm our findings.
Several studies included in our analysis showed that
treatment failure was associated with lineage 2 Beijing
family strains [43, 44]. Beijing family strains are also as-
sociated with drug resistance [56], which has been
reviewed previously [12, 22, 23]. Additionally, lineage 1
strains have been associated with more rapid response
to treatment in drug-susceptible TB cases in the USA
[57]. Thus, there is evidence for a relationship between
bacterial genotype and treatment outcome, at least in
certain populations or contexts. Future studies that care-
fully control for potential confounders that may impact
treatment failure are required to confirm these findings.
This type of information could be particularly important
to clinicians if it could inform the development of novel
diagnostic tools that test for bacterial genotypes associ-
ated with poor response to treatment and development
of drug resistance.
Variation between studies and implications for variation
in MTBC genotypes
There was variation in the sampling methods and repre-
sentativeness of the studies included in this systematic
review. The majority of studies were representative of
much smaller geographic locations than the national
level, and despite the large number of bacterial isolates
Fig. 5 Distribution of MTBC lineages over time by region. MTBC genotype distribution by region over time corresponding to results presented in
Additional file 1: Figure S3. The year 1990 represents all studies from 1990 to 1999, the year 2000 represents all studies from 2000 to 2009, and
the year 2010 represents all studies from 2010 to 2017. Indo-Oceanic lineage 1 is shown in pink, East Asian lineage 2 is shown in blue, East
African-Indian lineage 3 is shown in purple, Euro-American lineage 4 is shown in orange, and West African lineages 5 and 6 are shown in green.
Other/unknown strains are shown in gray and represent animal lineages, lineage 7, and strain types that were not identified by authors either
due to low frequency or unknown genetic patterns. Strain counts and sample sizes were summed across all studies within the given regions and
time periods to get proportions. There was no data from East Asia, West Asia, and Oceania in the 1990s, and therefore, these years are left blank
Table 1 Summary of random effects (RE) meta-analyses of relative risk (RR) of transmission chains associated with MTBC lineages
Lineage number Lineage name RR p value (RR) CI, lower CI, upper Q p value (Q) I2 (%) Number of studies
4 Euro-American 1.00
1 Indo-Oceanic 1.07 0.61 0.83 1.37 228.3 0.00 95.4 17
2 East Asian 1.24 0.01 1.07 1.45 220.6 0.00 97.8 20
3 East African-Indian 0.98 0.84 0.81 1.18 130.6 0.00 84.9 17
5, 6 West African 0.61 0.01 0.43 0.86 39.4 0.00 95.0 8
– Animal 0.79 0.02 0.64 0.96 7.43 0.28 18.0 7
– Unknown 0.56 0.00 0.40 0.79 70.5 0.00 92.0 12
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included in this study, they represented only a small
fraction of the total estimated TB cases. While the goal
of this study was to summarize the MTBC genotyping
data available, not to make nationally representative esti-
mates, it is important to note that this variation was not
distributed evenly throughout the world. There was less
information available about MTBC genotype distribution
in South America and Sub-Saharan Africa than in other
regions, and the data in Central and Eastern Asia repre-
sented a smaller proportion of all estimated TB cases
than elsewhere. Thus, the genetic diversity shown in the
map in Fig. 3 for these regions is likely less representa-
tive of the underlying populations.
Another source of variation that may impact represen-
tativeness is whether studies were biased towards includ-
ing either rural or urban populations. There is likely
greater MTBC genetic diversity in patients from urban
populations than patients from rural areas since urban
areas experience higher rates of travel and migration.
Most studies included in this analysis did not report the
urban/rural composition of their sample, and the bias
towards one or the other would likely vary depending on
study location. For example, the majority of the studies
included in our systematic review used samples collected
from public hospitals or reference laboratories. There-
fore, in countries such as India, where people in urban
areas may be more likely to seek care from private
health clinics [58], the urban population may be under-
represented and we may have underestimated genetic di-
versity. On the other hand, in countries such as Uganda,
where the rural population has limited access to public
health facilities [59], the rural population may be under-
represented and we may have overestimated genetic di-
versity. This highlights the importance of data from
prevalence surveys that use active surveillance tech-
niques to reach a broader subset of the population.
We also identified a significant amount of heterogen-
eity between studies in the meta-analysis of genetic clus-
tering associated with genotypes. One source of this
heterogeneity is likely methodological differences be-
tween the studies, such as genotyping method, sampling
method, and study duration, which have been shown to
impact genetic clustering [27, 28]. For example, duration
of sampling ranged from 2 months to 9 years, and geno-
typing methods ranged from the use of either spoligo-
typing or MLVA typing to the use of both methods
(Additional file 1: Table S4). Studies that used shorter
sampling durations may have missed transmission chains
and underestimated clustering, while studies that used
spoligotyping only may have overestimated clustering
[60]. An additional source of heterogeneity may be con-
founders that impact genetic clustering and transmis-
sion, such as social mixing, immigration, age structure,
comorbidities, and underlying TB incidence [27, 28].
These confounders likely also varied between these stud-
ies but were often not reported. For example, only 14 of
the studies reported HIV prevalence (range 0 to 91%),
only 6 reported proportion of immigrants (range 0 to
78%), and only 14 reported mean age of patients (range
25 to 50) included in the sample (Additional file 1: Table
S4). If social mixing was high in each of the studies, this
could have led us to overestimate the impact of genotype
on transmission chains, while if migration was high, this
could have led us to underestimate the presence of
transmission chains.
Study limitations
A limitation of this study is that we grouped strains
into seven lineages, which masks within-lineage vari-
ation. Distinct sub-lineages of the Beijing family are as-
sociated with differences in transmissibility in human
populations [61, 62], and lineage 4 contains both geo-
graphically widespread and restricted sub-lineages [49].
However, we propose that this was the best method as
it allowed us to (1) include a broad range of studies, in-
cluding those that did not report sub-lineages, and (2)
synthesize studies that used WGS- or PCR-based typing
together with studies that used methods more common
in resource-limited settings, such as spoligotyping and
MLVA typing.
Another limitation is that we did not include data from
WGS databases. A challenge of incorporating WGS data
Table 2 Summary of treatment failure studies
Source Location Years No. of
patients
Confounders adjusted for Findings RR/OR
[95% CI]
Parwati et al. [43] Indonesia 2000–2005 818 Drug resistance, non-adherence, age, diabetes
mellitus, and severity of radiological lesions
Lineage 2 Beijing family were
associated with treatment failure.
RR 1.94
[1.26, 3.0]
Chatterjee et al. [44] India 2004–2007 646 Multi-drug resistance Lineage 2 Beijing family were
associated with treatment failure.
OR 3.29
[1.29, 8.14]
Buu et al. [45] Vietnam 2003–2007 1106 Multi-drug resistance Lineage 2 Beijing family were not
associated with treatment failure.
OR 0.7
[0.3, 2.0]




1993–2004 1737 None (analysis included only drug-susceptible
strains)
Lineage 2 Beijing family were not
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is identifying study meta-data, such as sampling methods
and demographic characteristics of patients, linked with ge-
nomes. In addition, many of the WGS data available are
poised for phylogeographic studies and for examining the
presence of specific mutations [32, 49, 56], but are less rep-
resentative of the populations they are isolated from. These
data are often from outbreaks or studies of specific sub-
populations, which we excluded in this analysis. As WGS
data linked with meta-data become more available
(through prevalence surveys [63] and endeavors such as
ReSeqTB) including this data would be an important exten-
sion of our study. Our study supports these future studies
by illustrating the importance of using genome sequences
to determine phylogenetic lineages or sub-lineages. The
dataset we have created could be used to fill geographic
gaps in future WGS-based maps, particularly in regions
where WGS technology is unavailable, and to verify results
from convenience-based samples.
Conclusions
The evidence gathered in this systematic review support
a role for bacterial genetic diversity in understanding
global variation in TB disease. However, there are as-
pects of the studies that restrict our ability to confidently
attribute clinical characteristics to genotypes. In order to
address these conditions in the future, there will need to
be a shift in the design of MTBC strain diversity studies
such that data is collected in a way that is clinically and
epidemiologically informative, wherever possible. We en-
courage future studies to carefully consider potential
confounding variables in study design and analysis and
to make all genotypes and study meta-data publicly
available upon publication. We also encourage the ana-
lysis of less-studied strains from lineages 1 and 3 in
order to increase comparability with the relative abun-
dance of data on lineage 2 and lineage 4 strains. The evi-
dence presented in this study demonstrate these types of
data could potentially be used to create tools to inform
the clinical diagnosis and treatment of TB and improve
our understanding of the epidemiology of this disease.
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